Julie Dean

Statistics

Publications

Citations

2.1K

H-Index

Active since

2012

Affiliations

Intensive Care National Audit & Research Centre(Current)

Nottingham University Hospitals NHS Trust

Bayer (Germany)

Medway NHS Foundation Trust

University of Oxford

Julie Dean is an author at Intensive Care National Audit & Research Centre specializing in pharmacotherapy, primary outcome analysis, and 28-day mortality.

Publications per year

2012–2025

Publications

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi et al. · The Lancet · 2021 · 564 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +6

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 521 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2022 · 384 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 291 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +13

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2023 · 132 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

1–5 of 8